Clinical Trial Update: Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients [Phase 3]

View source ↗

Summary

A Phase 3 non-inferiority trial evaluating an MRNA-lncRNA model for low-risk triple-negative breast cancer, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Snippet

Sponsor: Fudan University | Conditions: Triple-negative Breast Cancer | Phase 3 | Status: NOT_YET_RECRUITING